[
  {
    "ts": null,
    "headline": "Medtronic: Solid Recent Performance But Better Options Available",
    "summary": "Medtronic: Solid Recent Performance But Better Options Available",
    "url": "https://finnhub.io/api/news?id=10c61258ca397c6e18b179be0654b65d5407e92a825505aa7e754c4f34ba9002",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750029697,
      "headline": "Medtronic: Solid Recent Performance But Better Options Available",
      "id": 135288698,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=10c61258ca397c6e18b179be0654b65d5407e92a825505aa7e754c4f34ba9002"
    }
  },
  {
    "ts": null,
    "headline": "Pharma manufacturing 'boom' faces high costs, potential delays",
    "summary": "Here are Big Pharma's plans to reshore manufacturing amid cost and policy headwinds.",
    "url": "https://finnhub.io/api/news?id=66d154f76f37f7661205f3a60a5df3661463c686dd634db2a8f356dcea85877d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749996037,
      "headline": "Pharma manufacturing 'boom' faces high costs, potential delays",
      "id": 135285407,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Here are Big Pharma's plans to reshore manufacturing amid cost and policy headwinds.",
      "url": "https://finnhub.io/api/news?id=66d154f76f37f7661205f3a60a5df3661463c686dd634db2a8f356dcea85877d"
    }
  },
  {
    "ts": null,
    "headline": "Halozyme Therapeutics: The Waters Become Muddled",
    "summary": "Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.",
    "url": "https://finnhub.io/api/news?id=0eb822c739bc2c6b6e2f9bd66e19b34754e600f484cf108b0175ab34f6bf9cec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749974539,
      "headline": "Halozyme Therapeutics: The Waters Become Muddled",
      "id": 135284784,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203542103/image_2203542103.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.",
      "url": "https://finnhub.io/api/news?id=0eb822c739bc2c6b6e2f9bd66e19b34754e600f484cf108b0175ab34f6bf9cec"
    }
  },
  {
    "ts": null,
    "headline": "Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY® (talquetamab-tgvs), the first U.S. Food and Drug Administration (FDA)-approved GPRC5D-directed bispecific antibody, and TECVAYLI® (teclistamab-cqyv), the first FDA-approved BCMA-directed bispecific antibody. The results show a high overall response rate (ORR) with durability in patients with triple-class exposed (TCE) relapsed/refractory multiple myel",
    "url": "https://finnhub.io/api/news?id=03f4f4b3a74815011b4019d83b875ecd98fb8e94cd1923f368d932fadfbd6fef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749971700,
      "headline": "Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease",
      "id": 135284841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY® (talquetamab-tgvs), the first U.S. Food and Drug Administration (FDA)-approved GPRC5D-directed bispecific antibody, and TECVAYLI® (teclistamab-cqyv), the first FDA-approved BCMA-directed bispecific antibody. The results show a high overall response rate (ORR) with durability in patients with triple-class exposed (TCE) relapsed/refractory multiple myel",
      "url": "https://finnhub.io/api/news?id=03f4f4b3a74815011b4019d83b875ecd98fb8e94cd1923f368d932fadfbd6fef"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease",
    "summary": "Johnson & Johnson: * INVESTIGATIONAL COMBINATION OF FIRST-IN-CLASS BISPECIFICSTALVEY® AND TECVAYLI® SHOWS DEEP AND DURABLE RESPONSES INHEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS...",
    "url": "https://finnhub.io/api/news?id=82401cdb98c7e39441fc32c215c1a66c94790fe1881dc9a8ab28653a139e19bb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749957728,
      "headline": "Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease",
      "id": 135279297,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * INVESTIGATIONAL COMBINATION OF FIRST-IN-CLASS BISPECIFICSTALVEY® AND TECVAYLI® SHOWS DEEP AND DURABLE RESPONSES INHEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS...",
      "url": "https://finnhub.io/api/news?id=82401cdb98c7e39441fc32c215c1a66c94790fe1881dc9a8ab28653a139e19bb"
    }
  }
]